Compare UNB & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNB | MXCT |
|---|---|---|
| Founded | 1891 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.6M | 136.2M |
| IPO Year | 1999 | 2021 |
| Metric | UNB | MXCT |
|---|---|---|
| Price | $23.76 | $1.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 5.8K | ★ 821.1K |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.76% | N/A |
| EPS Growth | ★ 25.52 | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.50 |
| P/E Ratio | $19.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.65 | $0.64 |
| 52 Week High | $26.54 | $1.86 |
| Indicator | UNB | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 45.43 | 57.66 |
| Support Level | $23.75 | $1.19 |
| Resistance Level | $24.56 | $1.54 |
| Average True Range (ATR) | 0.40 | 0.09 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 30.00 | 52.38 |
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The Company has one definable business segment, Union Bank, which provides full retail, commercial, municipal banking, and wealth management and trust services throughout its 18 branch banking locations, three loan centers, and several ATMs covering northern Vermont and northern New Hampshire. In addition, it also offers fiduciary and asset management services through its Asset Management Group.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.